Ocular Therapeutix, Inc. (OCUL)
NASDAQ
Healthcare
Biotechnology
$9.64
▲ +7.83%
Market Cap
$2.11B
Sector
Healthcare
Industry
Biotechnology
Beta
0.90
52-Wk Range
6.23-16.44
CEO
Pravin U. Dugel
Country
US
Currency
USD
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunc…
Open full interactive analysis & DCF →